Vincerx Pharma Q4 2022 Earnings Report $0.11 -0.04 (-24.47%) As of 01/22/2025 04:00 PM Eastern Earnings HistoryForecast Vincerx Pharma EPS ResultsActual EPS-$0.65Consensus EPS -$0.63Beat/MissMissed by -$0.02One Year Ago EPSN/AVincerx Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVincerx Pharma Announcement DetailsQuarterQ4 2022Date3/28/2023TimeN/AConference Call ResourcesVINC Earnings History Vincerx Pharma Earnings HeadlinesVincerx Pharma enters at-the-market equity offering dealJanuary 21 at 8:51 PM | msn.comVincerx Pharma Inc Ordinary SharesJanuary 14, 2025 | morningstar.com24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.January 23, 2025 | Crypto Swap Profits (Ad)Investor law firms question biotech merger's 'fairness'January 7, 2025 | bizjournals.comVINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINCJanuary 6, 2025 | businesswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vincerx Pharma, Inc. MergerJanuary 3, 2025 | markets.businessinsider.comSee More Vincerx Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vincerx Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vincerx Pharma and other key companies, straight to your email. Email Address About Vincerx PharmaVincerx Pharma (NASDAQ:VINC), a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.View Vincerx Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Verizon Communications (1/24/2025)NextEra Energy (1/24/2025)HCA Healthcare (1/24/2025)American Express (1/24/2025)AT&T (1/27/2025)Starbucks (1/28/2025)PACCAR (1/28/2025)Intuitive Surgical (1/28/2025)General Motors (1/28/2025)RTX (1/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
